Tiger Brokers

Ocular Therapeutix股价因竞争对手Kodiak在临床试验中获胜而暴跌，分析师称抛售反应过度

路透中文
Sep 29
BUZZ-<a href="https://laohu8.com/S/OCUL">Ocular Therapeutix</a>股价因竞争对手Kodiak在临床试验中获胜而暴跌，分析师称抛售反应过度

9月28日 - ** Ocular Therapeutix（OCUL.O）股价在午后交易中下跌18.8%，至7.84美元

** Kodiak Sciences公司（KOD.O）的实验性药物Zenkuda和tabirafusp-ted在针对湿性年龄相关性黄斑变性患者的后期临床试验中达到了主要目标（(link)），其视力改善效果与Regeneron公司（REGN.O）的重磅眼科药物aflibercept相当

** Ocular公司正在研发axpaxli，这是一种针对湿性年龄相关性黄斑变性（wet AMD）患者的长效竞争性治疗药物

** RBC资本市场分析师丽莎·沃尔特表示，“今日OCUL股价的抛售反应过度”，因为当前的估值“并未反映出axpaxli在湿性年龄相关性黄斑变性（wAMD）适应症上市3-4年后，极有可能成为一款销售额约10亿美元的药物”

** “我们仍然认为OCUL拥有定位最佳的长效治疗药物，”沃尔特补充道

** 科迪亚克科学公司（Kodiak Sciences）股价飙升189%至93.59美元，使该公司市值有望增加约38.5亿美元

** 包括今日盘中波动在内，OCUL年内累计下跌35%，KOD年内累计上涨221%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10